On September 13, 2023 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, reported it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper): Translating Science into Survival, being held September 20 – 23, 2023 in Milan, Italy (Press release, Sensei Biotherapeutics, SEP 13, 2023, View Source [SID1234635142]). The new data build on SNS-101’s preclinical safety and efficacy profile and provide additional insights into its conditionally active mechanism of action. SNS-101 is currently in a Phase 1/2 clinical study.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: SNS-101, a clinical-stage pH-dependent and TME-selective anti-VISTA antibody with favorable pharmacokinetic and safety characteristics, promotes anti-tumoral M1 macrophage polarization in PD-1 refractory settings
Presentation Type: Poster
Date and Time: Thursday, September 21, 2023, from 12:30 pm to 2:00 pm CET
Session: Poster Session A
The poster will be made available on the Sensei Bio website following the presentation.